Skip to content
Menu

Reported Earlier, Vivos Therapeutics Q3 EPS $(0.07) Beats $(0.42) Estimate, Sales $6.414M Beat $5.937M Estimate

Benzinga Newsdesk 2 days ago

NewsEarningsEarnings Beats

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Vivos Therapeutics (NASDAQ:VVOS) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.42) by 83.33 percent. This is a 85.71 percent increase over losses of $(0.49) per share

Vivos Therapeutics (NASDAQ:VVOS) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.42) by 83.33 percent. This is a 85.71 percent increase over losses of $(0.49) per share from the same period last year. The company reported quarterly sales of $6.414 million which beat the analyst consensus estimate of $5.937 million by 8.04 percent. This is a 5.44 percent decrease over sales of $6.783 million the same period last year.

Read at benzinga.com